Patient characteristics
| Characteristics . | Total (N = 245) . |
|---|---|
| Age,∗ median (range) | 62 (20-84) |
| Sex (male), n (%) | 160 (65.3) |
| Diagnosis,∗ n (%) | |
| DLBCL | 131 (53) |
| tFL | 76 (31) |
| HGBCL DH/TH | 23 (9.4) |
| HGBCL NOS | 8 (3.3) |
| T-cell–rich LBCL | 2 (0.8) |
| PMBCL | 5 (2.0) |
| Stage III-IV,∗ n (%) | 193 (79) |
| CNS involvement,∗ n (%) | 12 (5) |
| No. of previous therapy lines,∗ median (range) | 2 (2-6) |
| Previous SCT, n (%) | 69 (28) |
| Autologous SCT | 66 (27) |
| Autologous and allogeneic SCT | 3 (1) |
| CRP,† median (IQR), mg/dL | 1.11 (0.30-3.20) |
| Ferritin,† median (IQR), ng/mL | 638 (322-1204) |
| Neutrophils,† median (IQR), per μL | 3240 (2050-4510) |
| Platelets,† median (IQR), g/L | 179 (121-229) |
| Hb,† median (IQR), g/dL | 11.3 (9.7-12.6) |
| Characteristics . | Total (N = 245) . |
|---|---|
| Age,∗ median (range) | 62 (20-84) |
| Sex (male), n (%) | 160 (65.3) |
| Diagnosis,∗ n (%) | |
| DLBCL | 131 (53) |
| tFL | 76 (31) |
| HGBCL DH/TH | 23 (9.4) |
| HGBCL NOS | 8 (3.3) |
| T-cell–rich LBCL | 2 (0.8) |
| PMBCL | 5 (2.0) |
| Stage III-IV,∗ n (%) | 193 (79) |
| CNS involvement,∗ n (%) | 12 (5) |
| No. of previous therapy lines,∗ median (range) | 2 (2-6) |
| Previous SCT, n (%) | 69 (28) |
| Autologous SCT | 66 (27) |
| Autologous and allogeneic SCT | 3 (1) |
| CRP,† median (IQR), mg/dL | 1.11 (0.30-3.20) |
| Ferritin,† median (IQR), ng/mL | 638 (322-1204) |
| Neutrophils,† median (IQR), per μL | 3240 (2050-4510) |
| Platelets,† median (IQR), g/L | 179 (121-229) |
| Hb,† median (IQR), g/dL | 11.3 (9.7-12.6) |
CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma; HGBCL DH/TH, high-grade B-cell lymphoma double hit/triple hit; HGBCL NOS, high-grade B-cell lymphoma not otherwise specified; SCT, stem cell transplantation; tFL, transformed follicular lymphoma.
At screening.
Before lymphodepleting chemotherapy.